MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript March 24, 2026 MaxCyte, Inc. misses on earnings expectations. Reported EPS is $-0.09016 EPS, expectations were $-0.06505. Operator: Good ...
AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into ...
The Shift from Chemistry to Biological FactoriesHow Digital Code is Replacing Synthetic ChemicalsAs soon as early scientists ...
In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally ...
Morning Overview on MSN
RNA-guided CRISPR tool turns genes on with dose control
Researchers have built a series of CRISPR-based platforms that can switch endogenous genes on and, just as critically, dial ...
CRISPR is a powerful DNA-editing tool that has underpinned huge advancements in human health care in the last decade. It is a ...
Genome-editing technologies, particularly CRISPR-based systems, have rapidly advanced from experimental tools to platforms with broad applications across ...
1d
CD Bioparticles Launches Extrahepatic RNA Delivery Services to to Advance Nucleic Acid Therapeutics
CD Bioparticles announces the launch of comprehensive Extrahepatic RNA Delivery services. NEW YORK, NY, UNITED STATES, ...
Inventory software should keep multi-location stock accurate, automate reorders, flag exceptions, and plug cleanly into your POS/ecommerce, accounting, and 3PL tools. Use this guide to match the right ...
Emerging antiviral defense systems are expanding the conceptual and practical boundaries of genome editing. Across bacteria, archaea, and eukaryotes, hosts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results